Fairmount Funds Management, Director: Apogee Therapeutics APGE Sell · Filed 01/22

Trade details

Type: Insider sale
Amount: $133,525,000
Shares · price: 1,750,000 sh · $76.30 a share
Held after: 298,647 sh
Stock: Apogee Therapeutics APGE
Person: Fairmount Funds ManagementDirector
Trade date: 26/01/22
Filed: 26/01/22
Days to filing: 0 days

Sold 85.4% of holdings

Share of holding sold: 85.4%

Apogee Therapeutics trades, last 26 weeks

What else happened in Apogee Therapeutics around then

Filed or reported within 30 days of the trade day · 25/12/23~02/21

Fairmount Funds Management's recent trades

Fairmount Funds ManagementDirector, 10% Stockholder
Planned saleOruka Therapeutics
Planned sale
Oruka Therapeutics
ORKA
$300M
3,553,410 sh
$300M
Filed 07/01
Traded 07/01
Fairmount Funds ManagementDirector
Planned saleSpyre Therapeutics
Planned sale
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
SellSpyre Therapeutics
Sell
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
BuyViridian Therapeutics, Inc.\DE
Buy
Viridian Therapeutics, Inc.\DE
VRDN
$20M
1,176,470 sh
$20M
Filed 05/13
Traded 05/11
Fairmount Funds ManagementDirector
BuyZenas BioPharma
Buy
Zenas BioPharma
ZBIO
$3M
150,000 sh
$3M
Filed 04/01
Traded 03/31